NCT02278887View on ClinicalTrials.gov

Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

September 23, 2014

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2023

Conditions
Metastatic Melanoma
Interventions
PROCEDURE

Translational research

Before during and at progression/regression biopsies and blood will be taken for translational research

DRUG

Cyclophosphamide

The patient receives 2 days cyclophosphamide via IV to deplete T-cells.

DRUG

Fludarabine

The patient receives 5 days fludarabine via IV to deplete T-cells.

DRUG

Interleukin-2

After infusion of the TIL, the patient receives IL-2 to keep the TIL active.

DRUG

Ipilimumab infusion

In arm A patients will be treated with 4 infusion of ipilimumab

Trial Locations (2)

Unknown

CCIT Department of Oncology and Haematology Herlev Hospital, Copenhagen

1066CX

Netherlands Cancer Institute, Amsterdam

All Listed Sponsors
collaborator

Copenhagen University Hospital at Herlev

OTHER

lead

The Netherlands Cancer Institute

OTHER

NCT02278887 - Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter